Newsletter - February 16, 2017
Compassionate Use Rules are Better Than the “Right to Try” Laws
Recently “Right to Try” bills were introduced in the US Senate and Congress. Similar laws have been enacted in 33 states; however it was felt that creating a Federal law will have a stronger impact in getting companies to give experiment drugs to terminally ill patients. While the intent behind the bills is great, the execution is misplaced. Read More
Most Drug Approvals by FDA are Based on Clinical Trials in White People
There is significant lack of diversity in clinical trial populations. FDA approved 67 new drugs in 2015 and 2016, and of the total trial populations, 5-7% were African-Americans, 11-12% were Asians, while 76-79% were White. Women were more equally represented with about 40-48% study populations being female. Read More
Compassionate Use Rules are Better Than the “Right to Try” Laws
Recently “Right to Try” bills were introduced in the US Senate and Congress. Similar laws have been enacted in 33 states; however it was felt that creating a Federal law will have a stronger impact in getting companies to give experiment drugs to terminally ill patients. While the intent behind the bills is great, the execution is misplaced. Read More
Most Drug Approvals by FDA are Based on Clinical Trials in White People
There is significant lack of diversity in clinical trial populations. FDA approved 67 new drugs in 2015 and 2016, and of the total trial populations, 5-7% were African-Americans, 11-12% were Asians, while 76-79% were White. Women were more equally represented with about 40-48% study populations being female. Read More